Structure Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2026, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or modified a “Rule 10b5-1 trading arrangement” (as such term is defined in Item 408(a) of Regulation S-K).
| Type of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position | Action | Date | Rule 10b5-1(1) | Non-Rule 10b5-1(2) | Total ADSs to be sold(3) | Expiration Date |
| Ashley Hall, J.D.Chief Development Officer | Adoption | March 29, 2026 | X | | Up to 60,432 | September 30, 2027 |
| Blai Coll, M.D., Ph.D.Chief Medical Officer | Adoption | March 30, 2026 | X | | Up to 36,667 | September 30, 2027 |
| Xichen Lin, Ph.D.Chief Scientific Officer | Adoption | March 26, 2026 | X | | Up to 85,144 | March 31, 2027 |
| (1) | Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
| (2) | “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. |
| (3) | The plan provides for the sale of an aggregate of up to approximately the number of ADSs that have vested or may vest for each officer during the plan period, net of any ADSs the Company withholds to satisfy income tax withholding and remittance obligations in connection with the net settlement of the equity awards, the amount of which cannot currently be determined. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.